Table 3.
Associations between clinicopathological characteristics and GNG4 in the external validation cohort.
| Variable | Number of patients | GNG4 expression | ||
|---|---|---|---|---|
| Positive | Negative | P value | ||
| (N=22) | (N=36) | |||
| Age | 0.309 | |||
| >16 years | 28 (48.3%) | 13 (59.1%) | 15 (41.7%) | |
| ≤16 years | 30 (51.7%) | 9 (40.9%) | 21 (58.3%) | |
| Gender | 0.103 | |||
| female | 25 (43.1%) | 6 (27.3%) | 19 (52.8%) | |
| male | 33 (56.9%) | 16 (72.7%) | 17 (47.2%) | |
| Relapse | 0.003 | |||
| No | 43 (74.1%) | 11 (50.0%) | 32 (88.9%) | |
| Yes | 15 (25.9%) | 11 (50.0%) | 4 (11.1%) | |
| Metastasis | 0.011 | |||
| No | 37 (63.8%) | 9 (40.9%) | 28 (77.8%) | |
| Yes | 21 (36.2%) | 13 (59.1%) | 8 (22.2%) | |
| TNM | 0.02 | |||
| I | 22 (37.9%) | 13 (59.1%) | 9 (25.0%) | |
| II/III | 36 (62.1%) | 9 (40.9%) | 27 (75.0%) | |
| Site | 0.417 | |||
| Else | 9 (15.5%) | 5 (22.7%) | 4 (11.1%) | |
| Femur/Tibia | 49 (84.5%) | 17 (77.3%) | 32 (88.9%) | |
| Size | 0.417 | |||
| >6 cm | 29 (50.0%) | 13 (59.1%) | 16 (44.4%) | |
| ≤6 cm | 29 (50.0%) | 9 (40.9%) | 20 (55.6%) | |
Values in bold indicate a P value less than 0.05, indicating a statistically significant difference.